HR Execs on the Move

Medical University of South Carolina Health

www.muschealth.org

 
The Medical University of South Carolina (MUSC) is a public institution of higher learning the purpose of which is to preserve and optimize human life in South Carolina and beyond. The university provides an interprofessional environment for learning and discovery through education of health care professionals and biomedical scientists, research in the health sciences and provision of comprehensive health care.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Jim Perry
Chief Revenue Cycle Officer Profile
Austin Zoeller
Associate Chief Supply Chain Officer Profile
Darrick Paul
Chief People Officer Profile

Similar Companies

MicroMed Laboratories

MicroMed Laboratories is a Petaluma, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Golden Leaf Holdings

Built around a portfolio of recognized brands, Golden Leaf Holdings Incorporate is one of the largest cannabis oil and solution providers in North America. The Company leverages a strong management team with cannabis and food industry experience to complement its expertise in the extracting, refining and selling of cannabis oil, edibles and flower products. The Company has developed a strong consumer brand portfolio (“Golden Brands”) that includes the Golden, Proper, Chalice Farms, Liberty Reach and Jackpot Seaweed brands. In addition to leading branded products, Golden Leaf also maintains a foothold in the Oregon retail dispensary market with its award-winning chain of Chalice Farms retail stores.

Bio Alberta

Bio Alberta is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Easy Choice Health Plan

Easy Choice Health Plan is a Newport Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoCell MDx

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.